Developer of a medical vaccine intended to prevent and offer treatment of human disease caused by Bordetella pertussis. The company's vaccine is a live attenuated pertussis vaccine inducing the immune system to produce protective antibodies against B. pertussis infection, enabling patients to recover from whooping cough and other serious diseases.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Later Stage VC | 30-Mar-2020 | $4.3M | 000.00 | Completed | Clinical Trials - Phase 2 | |
6. Later Stage VC | 19-Dec-2018 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 2 | |
5. Angel (individual) | 07-Feb-2018 | 00000 | 000.00 | Completed | Clinical Trials - Phase 1 | |
4. Angel (individual) | 13-Apr-2017 | 000 | 000.00 | Completed | Clinical Trials - Phase 1 | |
3. Angel (individual) | 13-Nov-2015 | 00000 | 00.000 | Completed | Clinical Trials - Phase 1 | |
2. Grant | $11.1M | $3.81M | Completed | Clinical Trials - Phase 1 | ||
1. Angel (individual) | $3.81M | $3.81M | Completed | Clinical Trials - Phase 1 |
Name | Representing | Role | Since |
---|---|---|---|
Ariel Pablos-Mendez MD | ILiAD Biotechnologies | Board Member | 000 0000 |
Bin Yan Ph.D | ILiAD Biotechnologies | Board Member | 000 0000 |
Corey Horowitz | Network-1 Technologies | Board Member | 000 0000 |
Cuong Do | ILiAD Biotechnologies | Board Member | 000 0000 |
Eric Edidin | Self | Board Observer | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Endo Investors | Venture Capital | Minority | 000 0000 | 000000 0 | |
JEMS venture capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Network-1 Technologies | Corporation | Minority | 000 0000 | 000000 0 | |
SDS Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | |
Seedlings Life Science Ventures | Corporation | Minority | 000 0000 | 000000 0 |